- Home
- RLMD
as of 02-23-2026 2:41pm EST
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | CORAL GABLES |
| Market Cap: | 319.7M | IPO Year: | 2012 |
| Target Price: | $9.00 | AVG Volume (30 days): | 620.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.16 | EPS Growth: | 19.21 |
| 52 Week Low/High: | $0.24 - $5.12 | Next Earning Date: | 03-05-2026 |
| Revenue: | $13,070 | Revenue Growth: | 154.83% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -3.56 | Index: | N/A |
| Free Cash Flow: | -51757598.0 | FCF Growth: | N/A |
AI-Powered RLMD Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Relmada Therapeutics Inc. (RLMD)
Chief Executive Officer
Avg Cost/Share
$4.12
Shares
27,500
Total Value
$113,300.00
Owned After
1,300,000
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$4.12
Shares
11,665
Total Value
$48,059.80
Owned After
800,000
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| TRAVERSA SERGIO | RLMD | Chief Executive Officer | Dec 15, 2025 | Buy | $4.12 | 27,500 | $113,300.00 | 1,300,000 | |
| Shenouda Maged | RLMD | Chief Financial Officer | Dec 15, 2025 | Buy | $4.12 | 11,665 | $48,059.80 | 800,000 |
Compare RLMD vs Leading Stocks
See how RLMD stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "RLMD Relmada Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.